caa a22 4500 475787188 CHVBK 20180406123701.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1007/PL00008349 doi (NATIONALLICENCE)springer-10.1007/PL00008349 Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome [Elektronische Daten] [Dagmar l'Allemand, Urs Eiholzer, Michael Schlumpf, Hans Steinert, Walter Riesen] Cardiovascular risk factors in Prader-Willi syndrome (PWS, OMIM 176270) may be independently caused by overweight or hypothalamic growth hormone (GH) deficiency. The present observational study in 23 children with PWS, aged 0.3-14.6 years, focuses on the specific pattern, age-dependency and interrelation of cardiovascular risk factors, namely percentage fat mass and regional fat distribution, triglycerides (TG), lipoprotein cholesterols (LDL-C, HDL-C), lipoprotein (a) (Lp(a)), apolipoproteins A-I (Apo A-I) and B (Apo B), as well as on the longer-term effects of GH therapy (ca. 0.037 mg/kg per day for 3 years on average). We report that in children above 4 years, percentage body fat was increased in all and waist-to-hip-ratio (WHR) in 35%. Abnormal levels of LDL-C, Apo B, HDL-C and TG were found in 6, 7, 6 and 3 children, respectively. Lp(a) was above 300 mg/l in 5 patients and remained unchanged during GH therapy. However, percentage fat mass dropped to the upper normal range and WHR became normal in all patients receiving GH therapy, as did the ratio of LDL-C to HDL-C, subsequent to decreasing LDL-C and increasing HDL-C. Nevertheless, we could not find any significant correlation between parameters of total fat mass or fat distribution and serum lipid parameters, except for abdominal fat distribution (trunk-/leg-fat ratio) to TG before therapy. Conclusion Several cardiovascular risk factors are already present in prepubertal children with Prader-Willi-syndrome and they are improved by growth hormone treatment, acting both on body composition and lipid metabolism. Springer-Verlag Berlin Heidelberg, 2000 Key words Prader-Willi syndrome nationallicence Growth hormone therapy nationallicence Cardiovascular risk factors nationallicence Body composition nationallicence Lipids nationallicence AbbreviationsApo A-1 apolipoprotein A-1 nationallicence Apo-B apolipoprotein B nationallicence DEXA dual-energy X-ray absorptiometry nationallicence GH growth hormone nationallicence HDL-C high density lipoprotein cholesterol nationallicence LDL-C low density lipoprotein cholesterol nationallicence Lp(a) lipoprotein (a) nationallicence PWS Prader-Willi syndrome nationallicence TC total cholesterol nationallicence TG triglycerides nationallicence WHR waist/hip ratio nationallicence l'Allemand Dagmar Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut Eiholzer Urs Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut Schlumpf Michael Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut Steinert Hans Department of Nuclear Medicine, University of Zurich, Zurich, Switzerland, CH aut Riesen Walter Institute of Clinical Chemistry and Haematology, Kantonsspital, St. Gallen, Switzerland, CH aut https://doi.org/10.1007/PL00008349 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/PL00008349 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- l'Allemand Dagmar Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut NATIONALLICENCE 700 1- Eiholzer Urs Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut NATIONALLICENCE 700 1- Schlumpf Michael Foundation Growth Puberty Adolescence, Moehrlistrasse 69, 8006 Zurich, Switzerland e-mail: mail@childgrowth.org Tel.: +41-1-3643700, Fax +41-1-3643701, CH aut NATIONALLICENCE 700 1- Steinert Hans Department of Nuclear Medicine, University of Zurich, Zurich, Switzerland, CH aut NATIONALLICENCE 700 1- Riesen Walter Institute of Clinical Chemistry and Haematology, Kantonsspital, St. Gallen, Switzerland, CH aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer